Patient and disease characteristics of the study cohort
| Characteristic . | OHI− (n = 70) . | OHI+ (n = 65) . | All (N = 135) . |
|---|---|---|---|
| Age at diagnosis, median (25%-75%), y | 66 (54-77) | 64 (55-69) | 64 (55-72) |
| Sex, n (%) | |||
| Female | 31 (44.2) | 27 (41.5) | 58 (43) |
| Male | 39 (55.7) | 38 (58.5) | 77 (57) |
| Diagnosis, n (%) | |||
| B-NHL | 41 (58.6) | 39 (67.7) | 80 (59.2) |
| DLBCL | 23 (33.0) | 20 (31.0) | 43 (32) |
| IVLBCL | 6 (8.6) | 8 (12.3) | 14 (10.4) |
| FL | 5 (7.1) | 3 (4.6) | 8 (6) |
| MZL | 1 (1.4) | 2 (3.1) | 3 (2.2) |
| THRLBCL | 1 (1.4) | 2 (3.1) | 3 (2.2) |
| Other B-NHL | 5 (7.1) | 4 (7.7) | 9 (6.6) |
| Mature T-cell lymphoma | 20 (28.6) | 21 (32.3) | 41 (30) |
| PTCL, NOS | 4 (6) | 7 (10.7) | 11 (8.1) |
| AITL | 3 (4.2) | 2 (3.1) | 5 (3.7) |
| ALCL | 0 (0) | 4 (6.1) | 4 (3) |
| Extranodal T/NK | 4 (6) | 1 (1.5) | 5 (3.7) |
| PCγδTCL | 3 (4.2) | 0 (0) | 3 (2.2) |
| Other T-cell lymphoma | 6 (8.6) | 7 (10.7) | 13 (9.6) |
| HL | 5 (7.7) | 5 (7.7) | 10 (7.4) |
| EBV+∗ | 14 (20)† | 6 (9)‡ | 20 (15) |
| Characteristic . | OHI− (n = 70) . | OHI+ (n = 65) . | All (N = 135) . |
|---|---|---|---|
| Age at diagnosis, median (25%-75%), y | 66 (54-77) | 64 (55-69) | 64 (55-72) |
| Sex, n (%) | |||
| Female | 31 (44.2) | 27 (41.5) | 58 (43) |
| Male | 39 (55.7) | 38 (58.5) | 77 (57) |
| Diagnosis, n (%) | |||
| B-NHL | 41 (58.6) | 39 (67.7) | 80 (59.2) |
| DLBCL | 23 (33.0) | 20 (31.0) | 43 (32) |
| IVLBCL | 6 (8.6) | 8 (12.3) | 14 (10.4) |
| FL | 5 (7.1) | 3 (4.6) | 8 (6) |
| MZL | 1 (1.4) | 2 (3.1) | 3 (2.2) |
| THRLBCL | 1 (1.4) | 2 (3.1) | 3 (2.2) |
| Other B-NHL | 5 (7.1) | 4 (7.7) | 9 (6.6) |
| Mature T-cell lymphoma | 20 (28.6) | 21 (32.3) | 41 (30) |
| PTCL, NOS | 4 (6) | 7 (10.7) | 11 (8.1) |
| AITL | 3 (4.2) | 2 (3.1) | 5 (3.7) |
| ALCL | 0 (0) | 4 (6.1) | 4 (3) |
| Extranodal T/NK | 4 (6) | 1 (1.5) | 5 (3.7) |
| PCγδTCL | 3 (4.2) | 0 (0) | 3 (2.2) |
| Other T-cell lymphoma | 6 (8.6) | 7 (10.7) | 13 (9.6) |
| HL | 5 (7.7) | 5 (7.7) | 10 (7.4) |
| EBV+∗ | 14 (20)† | 6 (9)‡ | 20 (15) |
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; EBV+, Epstein-Barr virus positive; FL, follicular lymphoma; IVLBCL, intravascular large B-cell lymphoma; MZL, marginal zone lymphoma; NOS, not otherwise specified; PCγδTCL, primary cutaneous γ/δ T-cell lymphoma; PTCL, peripheral T-cell lymphoma; THRLBCL, T-cell/histiocyte-rich large B-cell lymphoma.
Either immunoglobulin M or polymerase reaction chain positive.
EBV+ OHI+ patients: 11 T-cell lymphoma, 2 B-NHL, and 1 HL.
EBV+ OHI− patients: 3 T-cell lymphoma, 2 B-NHL, and 1 HL.